<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:DNLI (USA) Also Trade In: Germany

Denali Therapeutics Inc $ 15.17 0.77 (5.35%)

Volume:
945,223
Avg Vol (1m):
307,230
Market Cap $:
1.45 Bil
Enterprise Value $:
1.05 Bil
P/E (TTM):
0.00
P/B:
3.12
Warning! GuruFocus has detected 1 Severe warning sign with DNLI. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for DNLI (Denali Therapeutics) from 2017 to Oct 22 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Denali Therapeutics stock (DNLI) PE ratio as of Oct 22 2019 is 0. More Details

Denali Therapeutics PE Ratio (TTM) Chart

EMBED

Denali Therapeutics PE Ratio (TTM) Historical Data

Total 487
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Denali Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2019-10-220.0 2019-08-200.0
2019-10-210.0 2019-08-190.0
2019-10-180.0 2019-08-160.0
2019-10-170.0 2019-08-150.0
2019-10-160.0 2019-08-140.0
2019-10-150.0 2019-08-130.0
2019-10-140.0 2019-08-120.0
2019-10-110.0 2019-08-090.0
2019-10-100.0 2019-08-080.0
2019-10-090.0 2019-08-070.0
2019-10-080.0 2019-08-060.0
2019-10-070.0 2019-08-050.0
2019-10-040.0 2019-08-020.0
2019-10-030.0 2019-08-010.0
2019-10-020.0 2019-07-310.0
2019-10-010.0 2019-07-300.0
2019-09-300.0 2019-07-290.0
2019-09-270.0 2019-07-260.0
2019-09-260.0 2019-07-250.0
2019-09-250.0 2019-07-240.0
2019-09-240.0 2019-07-230.0
2019-09-230.0 2019-07-220.0
2019-09-200.0 2019-07-190.0
2019-09-190.0 2019-07-180.0
2019-09-180.0 2019-07-170.0
2019-09-170.0 2019-07-160.0
2019-09-160.0 2019-07-150.0
2019-09-130.0 2019-07-120.0
2019-09-120.0 2019-07-110.0
2019-09-110.0 2019-07-100.0
2019-09-100.0 2019-07-090.0
2019-09-090.0 2019-07-080.0
2019-09-060.0 2019-07-050.0
2019-09-050.0 2019-07-040.0
2019-09-040.0 2019-07-030.0
2019-09-030.0 2019-07-020.0
2019-09-020.0 2019-07-010.0
2019-08-300.0 2019-06-280.0
2019-08-290.0 2019-06-270.0
2019-08-280.0 2019-06-260.0
2019-08-270.0 2019-06-250.0
2019-08-260.0 2019-06-240.0
2019-08-230.0 2019-06-210.0
2019-08-220.0 2019-06-200.0
2019-08-210.0 2019-06-190.0

Denali Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Biotechnology » Biotechnology NAICS : 325414 NAICS : 2836
Traded in other countries 4DN.Germany DNLI.USA
Address 151 Oyster Point Boulevard, 2nd Floor, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle) and others.